Urine metabolic fingerprinting using LC-MS and GC-MS reveals metabolite changes in prostate cancer: A pilot study

Journal of Pharmaceutical and Biomedical Analysis

Volumn 111, Issue , 2015, Pages 351-361

  Struck Lewicka, Wiktoria ^a   Kordalewska, Marta ^a   Bujak, Renata ^a   Yumba Mpanga, Arlette ^a   Markuszewski, Marcin ^a   Jacyna, Julia ^a   Matuszewski, Marcin ^a   Kaliszan, Roman ^a   Markuszewski, Michał J ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

GC MS; LC MS; Potential biomarkers; Prostate cancer; Untargeted metabolomics

Indexed keywords

TUMOR MARKER;

CASE CONTROL STUDY; DISCRIMINANT ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLISM; METABOLOMICS; MIDDLE AGED; PILOT STUDY; PRINCIPAL COMPONENT ANALYSIS; PROCEDURES; PROSTATE TUMOR; REGRESSION ANALYSIS; URINE;

BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISCRIMINANT ANALYSIS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MASS SPECTROMETRY; METABOLOMICS; MIDDLE AGED; PILOT PROJECTS; PRINCIPAL COMPONENT ANALYSIS; PROSTATIC NEOPLASMS;

EID: 84939950433     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2014.12.026     Document Type: Article

References (41)

1. Damber J.E., Aus G. Prostate cancer. Lancet 2008, 371:1710-1721.
2. DeSantis C.E., Lin C.C., Mariotto A.B., Siegel R.L., Stein K.D., Kramer J.L., Alteri R., Robbins A.S., Jemal A. Cancer treatment and survivorship statistics. CA: Cancer J. Clin. 2014, 64(4):252-271.
3. Gerlinger M., Catto J.W., Orntoft T.F., Real F.X., Zwarthoff E.C., Swanton C. Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications. Eur. Urol. 2014, 10.1016/j.eururo.2014.04.014.
4. Fraser M., Berlin A., Bristow R.G., van der Kwast T. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. Urol. Oncol. 2014, 10.1016/j.urolonc.2013.10.020.
5. Kilpeläinen T.P., Tammela T.L., Roobol M., Hugosson J., Ciatto S., Nelen V., Moss S., Määttänen L., Auvinen A. False-positive screening results in the European randomized study of screening for prostate cancer. Eur. J. Cancer 2011, 47(18):2698-2705.
6. Verma M., Patel P., Verma M. Biomarkers in prostate cancer epidemiology. Cancers 2011, 3:3773-3798.
7. Stephan C., Ralla B., Jung K. Prostate-specific antigen and other serum and urine markers in prostate cancer. Biochim. Biophys. Acta 2014, 1846:99-112.
8. Velonas V.M., Woo H.H., Remedios C.G., Assinder S.J. Current status of biomarkers for prostate cancer. Int. J. Mol. Sci. 2013, 14:11034-11060.
9. Jerónimo C., Bastian P.J., Bjartell A., Carbone G.M., Catto J.W., Clark S.J., Henrique R., Nelson W.G., Shariat S.F. Epigenetics in prostate cancer: biologic and clinical relevance. Eur. Urol. 2011, 60:753-766.
10. Dobosy J.R., Roberts J.L., Fu V.X., Jarrard D.F. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J. Urol. 2007, 177:822-831.
11. Key T.J. Nutrition, hormones and prostate cancer risk: results from the European prospective investigation into cancer and nutrition. Recent Results Cancer Res. 2014, 202:39-46.
12. Friedman A.E. The Estradiol-Dihydrotestosterone model of prostate cancer. Theor. Biol. Med. Model 2005, 2:10.
13. Bosland M.C., Mahmoud A.M. Hormones and prostate carcinogenesis: androgens and estrogens. J. Cardiogr. 2011, 10:33.
14. Rodriguez-Gonzalo E., Garcia-Gómez D., Carabias-Martinez R. Development and validation of a hydrophilic interaction chromatography-tandem mass spectrometry method with on-line polar extraction for the analysis of urinary nucleosides. Potential application in clinical diagnosis. J. Chromatogr. A 2011, 1218:9055-9063.
15. Szymańska E., Markuszewski M.J., Markuszewski M., Kaliszan R. Altered levels of nucleoside metabolite profiles in urogenital tract cancer measured by capillary electrophoresis. J. Pharm. Biomed. Anal. 2010, 53:1305-1312.
16. Kumar V., Dwivedi D.K., Jagannathan N.R. High-resolution NMR spectroscopy of human body fluids and tissues in relation to prostate cancer. NMR Biomed. 2014, 27:80-89.
17. Decelle E.A., Cheng L.L. High-resolution magic angle spinning 1H MRS in prostate cancer. NMR Biomed. 2014, 27:90-99.
18. Struck W., Siluk D., Yumba-Mpanga A., Markuszewski M., Kaliszan R., Markuszewski M.J. Liquid chromatography tandem mass spectrometry study of urinary nucleosides as potential cancer markers. J. Chromatogr. A 2013, 1283:122-131.
19. Kami K., Fujimori T., Sato H., Sato M., Yamamoto H., Ohashi Y., Sugiyama N., Ishihama Y., Onozuka H., Ochiai A., Esumi H., Soga T., Tomita M. Metabolomic profiling of lung and prostate tumor tissues by capillary electrophoresis time-of-flight mass spectrometry. Metabolomics 2013, 9:444-453.
20. Jiang Y., Cheng X., Wang C., Ma Y. Quantitative determination of sarcosine and related compounds in urinary samples by liquid chromatography with tandem mass spectrometry. Anal. Chem. 2010, 82:9022-9027.
21. Giskeødegård G.F., Bertilsson H., Selnæs K.M., Wright A.J., Bathen T.F., Viset T., Halgunset J., Angelsen A., Gribbestad I.S., Tessem M.B. Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness. PLoS ONE 2013, 8:e62375.
22. Zhang T., Watson D.G., Wang L., Abbas M., Murdoch L., Bashford L., Ahmad I., Lam N.Y., Ng A.C., Leung H.Y. Application of holistic liquid chromatography-high resolution mass spectrometry based urinary metabolomics for prostate cancer detection and biomarker discovery. PLoS ONE 2013, 8:e65880.
23. Zhou X., Mao J., Ai J., Deng Y., Roth M.R., Pound C., Henegar J., Welti R., Bigler S.A. Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics. PLoS ONE 2012, 7:e48889.
24. Mondul A.M., Moore S.C., Weinstein S.J., Männistö S., Sampson J.N. Albanes D: 1-stearoylglycerol is associated with risk of prostate cancer: results from serum metabolomic profiling. Metabolomics 2014, 10:1036-1041.
25. Robertson B.-J.W., Kim Y.-M., Zink E.M., Hallaian K.A., Zhang Q., Madupu R., Waters K.M., Metz T.O. A statistical analysis of the effects of urease pre-treatment on the measurement of the urinary metabolome by gas chromatography-mass spectrometry. Metabolomics 2014, 10:897-908.
26. Dunn W.B., Broadhurst D., Begley P., Zelena E., Francis-McIntyre S., Anderson N., Brown M., Knowles J.D., Halsall A., Haselden J.N., Nicholls A.W., Wilson I.D., Kell D.B., Goodacre R., The Human Serum Metabolome (HUSERMET) Consortium Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat. Protoc. 2011, 6:1060-1083.
27. Warburg O. On respiratory impairment in cancer cells. Science 1956, 124:269-270.
28. Muñoz-Pinedo C., El Mjiyad N., Ricci J.-E. Cancer metabolism: current perspectives and future directions. Cell Death Dis. 2012, 3:e248.
29. Armitage E.G., Barbas C. Metabolomics in cancer biomarker discovery: current trends and future perspectives. J. Pharm. Biomed. Anal. 2014, 87:1-11.
30. Zhang A., Yan G., Han Y., Wang X. Metabolomics approaches and applications in prostate cancer research. Appl. Biochem. Biotechnol. 2014, 174:6-12.
31. Wu H., Liu T., Ma C., Xue R., Deng C., Zeng H., Shen X. GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization. Anal. Bioanal. Chem. 2011, 401:635-646.
32. McDunn J.E., Li Z., Adam K.-P., Neri B.P., Wolfert R.L., Milburn M.V., Lotan Y., Wheeler T.M. Metabolomic signatures of aggressive prostate cancer. Prostate 2013, 73:1547-1560.
33. Lin L., Huang Z., Gao Y., Yan X., Xing J., Hang W. LC-MS based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery. J. Proteome Res. 2011, 10:1396-1405.
34. Cheng Y., Xie G., Chen T., Qiu Y., Zou X., Zheng M., Tan B., Feng B., Dong T., He P., Zhao L., Zhao A., Xu L.X., Zhang Y., Jia W. Distinct urinary metabolic profile of human colorectal cancer. Distinct urinary metabolic profile of human colorectal cancer. J. Proteome Res. 2012, 11:1354-1363.
35. Albericea J.V., Amaralc A.F.S., Armitagea E.G., Lorented J.A., Algabae F., Carrilhob E., Márquezc M., Garcíaa A., Malatsc N., Barbas C. Searching for urine biomarkers of bladder cancer recurrence using a liquid chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry metabolomics approach. J. Chromatogr. A 2013, 1318:163-170.
36. Hirayama A., Kami K., Sugimoto M., Sugawara M., Toki N., Onozuka H., Kinoshita T., Saito N., Ochiai A., Tomita M., Esumi H., Soga T. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 2009, 69:4918-4925.
37. Huang Z., Lin L., Gao Y., Chen Y., Yan X., Xing J., Hang W. Bladder cancer determination via two urinary metabolites: a biomarker pattern approach. Mol. Cell. Proteomics 2011, 10:1-10.
38. Ganti S., Taylor S.L., Kim K., Hoppeli C.L., Guo L., Yang J., Evans C., Weiss R.H. Urinary acylcarnitines are altered in human kidney cancer. Int. J. Cancer 2012, 130:2791-2800.
39. Schram K.H. Urinary nucleosides. Mass Spectrom. Rev. 1998, 17:131-251.
40. Struck W., Waszczuk-Jankowska M., Kaliszan R., Markuszewski M.J. The state-of-the-art determination of urinary nucleosides using chromatographic techniques hyphenated with advanced bioinformatic methods. Anal. Bioanal. Chem. 2011, 401:2039-2050.
41. Hsu W.Y., Chen C.J., Huang Y.C., Tsai F.J., Jeng L.B., Lai C.C. Urinary nucleosides as biomarkers of breast, colon, lung, and gastric cancer in Taiwanese. PLoS ONE 2013, 8:e81701.